About Us | Contact

Nazha F Abughali Investigator

Pediatric Infectious Diseases NPI1780692459
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$5,525.53
from 23 payments in the last 6 years

Total Cash or Cash Equivalent

$3,140.00
from 1 payments in the last 6 years

Total In-kind Items & Services

$2,385.53
from 22 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
08/15/2019 General (Non-Research) In-kind items and services Food and Beverage $46.05 Details
Payment from AstraZeneca Pharmaceuticals LP
Payment Record ID 685910161
08/15/2019 General (Non-Research) In-kind items and services Travel and Lodging $202.27 Details
Payment from AstraZeneca Pharmaceuticals LP
Payment Record ID 685900255
08/15/2019 General (Non-Research) In-kind items and services Travel and Lodging $104.64 Details
Payment from AstraZeneca Pharmaceuticals LP
Payment Record ID 685865497
08/15/2019 General (Non-Research) In-kind items and services Travel and Lodging $28.71 Details
Payment from AstraZeneca Pharmaceuticals LP
Payment Record ID 685842855
08/15/2019 General (Non-Research) In-kind items and services Food and Beverage $24.32 Details
Payment from AstraZeneca Pharmaceuticals LP
Payment Record ID 685786793
08/15/2019 General (Non-Research) In-kind items and services Travel and Lodging $387.69 Details
Payment from AstraZeneca Pharmaceuticals LP
Payment Record ID 685678829
08/15/2019 General (Non-Research) In-kind items and services Food and Beverage $122.25 Details
Payment from AstraZeneca Pharmaceuticals LP
Payment Record ID 685339491
08/15/2019 General (Non-Research) In-kind items and services Food and Beverage $56.73 Details
Payment from AstraZeneca Pharmaceuticals LP
Payment Record ID 685315865
08/15/2019 General (Non-Research) In-kind items and services Food and Beverage $57.44 Details
Payment from AstraZeneca Pharmaceuticals LP
Payment Record ID 685231083
08/15/2019 General (Non-Research) In-kind items and services Food and Beverage $22.66 Details
Payment from AstraZeneca Pharmaceuticals LP
Payment Record ID 685120327
10/15/2019 General (Non-Research) In-kind items and services Food and Beverage $50.00 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681467869
10/15/2019 General (Non-Research) In-kind items and services Food and Beverage $50.00 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681467867
10/15/2019 General (Non-Research) In-kind items and services Food and Beverage $50.00 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681467865
10/15/2019 General (Non-Research) In-kind items and services Food and Beverage $25.00 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 681467863
11/21/2019 General (Non-Research) In-kind items and services Travel and Lodging $56.64 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 679335185
11/21/2019 General (Non-Research) In-kind items and services Travel and Lodging $53.25 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 679335181
10/15/2019 General (Non-Research) In-kind items and services Travel and Lodging $416.78 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 679335177
10/15/2019 General (Non-Research) In-kind items and services Travel and Lodging $306.99 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 679335173
10/24/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $3140.00 Details
Payment from Gilead Sciences, Inc.
Payment Record ID 679255879
09/07/2016 Research In-kind items and services $83.55 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Clinical Trials Gov ID NCT02325791
Payment Record ID 358596388
09/07/2016 Research In-kind items and services $33.37 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Clinical Trials Gov ID NCT02325791
Payment Record ID 358596384
09/07/2016 Research In-kind items and services $144.54 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Clinical Trials Gov ID NCT02325791
Payment Record ID 358596380
09/08/2016 Research In-kind items and services $62.65 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Clinical Trials Gov ID NCT02325791
Payment Record ID 358596366
;